Naira Adamyan
Head of the Representative Office of Janssen Pharmaceutica NV, Russia and CIS
Pharmaceutical division of Johnson & Johnson
Naira Adamyan started her career in the pharmaceutical business in Janssen-Cilag in 1997 as a medical representative. Through the years she has demonstrated impressive career development as Product Manager, Franchise Manager and then Business Unit Manager.
In 2004 Naira took the position of Executive Director of Health Economics & Pricing for Janssen-Cilag. Through effective management, the Health Economics & Pricing department achieved significant results which became one of the key success factors for Janssen-Cilag in Russia. In February 2006 Naira was promoted to the position of Managing Director for Janssen-Cilag, Russia and on January 1st, 2010 she became the Head of the Representative office of Janssen Pharmaceutica NV, Russia and CIS.
Naira devotes significant time to pharmaceutical industry joint issues recognition and coordination. In 2007 Naira was elected Vice-Chair for Russia PhRMA LAWG followed by chairing position in 2008. In 2009 InPharma was founded as legal entity to LAWG. Naira has been AIPM Board member starting in 2011.
Naira is a Medical Doctor, holds a PhD in immunology and MBA from Thunderbird University, USA. Naira is married and has a daughter.
Victoria Anashkina
Country Director - Russian Federation
Amgen Email:
Victoria is a Medical Doctor by education and has a diploma from the Chartered Institute of Marketing (UK) Marketing and Diploma on Organisational Psychology from INSEAD (Fr). After graduating from the medical institute in 1989, Victoria worked as a doctor. In 1993 she began her career in the Russian Pharmaceutical market as a medical representative.
Victoria had rich experience in the pharma market from 1993-2006. She has taken different management positions in Zeneca Pharmaceuticals, AstraZeneca UK LTD and Polpharma mainly in the field of marketing, business development and general management. Victoria has been the Head of Russian office of Amgen since 2006.
Rhona S. Applebaum VP, Chief Scientific & Regulatory Officer
The Coca-Cola Company Email:
Dr. Rhona S. Applebaum is the Vice President and Chief Scientific and Regulatory Officer at The Coca-Cola Company where she leads the Scientific and Regulatory Affairs (SRA) department and the Beverage Institute for Health and Wellness (BI). SRA/BI is responsible for driving evidence-based scientific research programs for key platforms in nutrition, health, and food safety; developing and advancing science-based regulatory strategies; communicating company positions on science and regulatory matters; providing systems guidance on regulatory, food safety, nutrition and health issues and policies globally; and working with key stakeholder groups to advance dialogue and understanding related to critical issues concerning the Company's products, policies and program. Dr. Applebaum joined The Coca-Cola
Company in 2004.
Dr. Applebaum serves on the Science Advisory Board of the U.S. Food and Drug Administration (FDA), the Department of State's Advisory Committee on International and Economic Policy, the Institute of Medicine‟s Food Forum and the Institute of Food Technologists‟ Senior Food Officials Committee. She serves on the Grocery Manufacturers of America‟s Science and Regulatory Affairs Committee, and the American Beverage Association‟s Health and Nutrition Committee. Additionally, Dr. Applebaum serves on the Board of Advisors for the University of Georgia‟s Center for Food Safety and the Forsyth Health Foundation, and participates as a member of the University of Massachusetts (Amherst) Food Science Strategic Policy Alliance.
Tiffany M. Atwell Director of Global Government Affairs
Abbott Russia Email:
Tiffany McCullen Atwell came to Abbott from the U.S. Senate Finance Committee working on international trade issues for the Chairman of the Committee in 2007 and most recently has served as director for Global Government Affairs focusing on Russia, India and supporting the HIV business. Throughout her career she has focused on international issues impacting U.S. companies. In addition, she previously worked in the U.S. Government at the U.S. State Department and U.S. Department of Commerce.
Mrs. Atwell holds a masters degree in public administration from North Carolina Central University, United States.
Ekaterina Bilyk
Project Manager
Ekaterina Bilyk graduated from the Institute of Nuclear Power engineering. Her work experience includes development and implementation of enterprise information systems as well as analysis of business processes. Now her main area is the management of innovative pharmaceutical projects from research to industrial manufacturing.
Medbiopharm is a Russian Innovation Company, located in Obninsk, in the center of Russia. The main activity of the company is research and development of active molecules. We provide the full scope of work required for the conversion of active molecules into products demanded in a pharmaceutical or food market. Our key features are a strong project management team and the attraction of the leading Russian and foreign researchers as idea carriers and experts. Medbiopharm also has strong partner relationship with leading Russia research institutes.
Dr. Viacheslav Burmistrov, M.D., PhD
Medical & Regulatory Director Russia & CIS
Eli Lilly and Company
Viacheslav is the Medical Director at Eli Lilly, Russia and CIS. He is responsible for medical and regulatory affairs, as well as for clinical operations. Viacheslav has been working in pharma industry for 10 years and has vigorous experience in clinical operations and medical affairs. He worked in Eli Lilly as a CRA and later on in a position of a clinical research physician, then led the medical department in the Russian local pharmaceutical company. He moved back to Eli Lilly last year as the Head of Clinical Operations, then moved to the Medical Director position. Viacheslav is a medical doctor with post-graduate qualification in psychiatry and PhD in clinical pharmacology.
Scott E. Campbell, PhD
Executive Director and Chief Executive Officer
Foundation for the National Institutes of Health
Dr. Scott Campbell is Executive Director and Chief Executive Officer of the Foundation for the National Institutes of Health (FNIH). Dr. Campbell joined the organization in July 2010, previously serving as National Vice President of Research Programs at the American Diabetes Association (ADA) from 2001-2010.
Dr. Campbell serves to guide and strengthen the mission of FNIH, while supporting the National Institutes of Health (NIH) through a wide range of initiatives that advance scientific
research to improve human health. Since joining FNIH, Dr. Campbell has worked with the FNIH Board of Directors and senior leadership to develop a three year comprehensive strategic plan that will further enhance the foundation‟s goals and initiatives. Supporting the NIH mission and aligning with the current NIH priorities, the plan establishes the FNIH priorities and direction for the coming years, including a focus on programs in the areas of global health, translational research, and research education and training.
Prior to the ADA, Dr. Campbell spent 12 years in academia at the Michael Reese Hospital in Chicago, the University of Missouri and the University of South Dakota. His primary area of research interest was hypertension, heart failure and the renin-angiotensin system. Dr. Campbell holds a Ph.D. in Basic Biomedical Sciences from the University of South Florida. He has authored numerous peer-reviewed articles, reviews and book chapters.
Irina Dorokhova
Senior Director, Government Affairs Russia & CEE
Johnson & Johnson
Irina Dorokhova started her career in the pharmaceutical industry in 1996. Over the years, Irena demonstrated results and made career developments in the “Pfizer” company. Irina took the position of Business Development in Endocrinology Director; Marketing and Strategic Planning Director; and External and Corporate Affairs Director.
Since 2006, Irina has been working at Johnson & Johnson Company as Senior Director Government Affairs. In 2008, her responsibilities expanded to include Central Eastern Europe countries.
Irina actively participates in the work of Russian professional associations and, on the corporate level, she is a member of a series of working groups in PhRMA* и EFPIA**, and she is chairman of the working group on Russia in EFPIA. Irina has a degree in medical science and readership in endocrinology. She is married and has a daughter.
Igor Friedmann
Country General Manager Russia, CIS Becton Dickinson
Igor Friedmann is BD‟s Country General Manager in Russia and is responsible for all of BD‟s operations in the Russian Federation and throughout the CIS countries. He began his career with BD in 2006 as a business manager for Russia and the CIS and was appointed to his current position in December 2009.
Prior to joining BD, Mr. Friedmann held senior management positions with several global pharmaceutical companies. From 2006-2008 he was based in Moscow as the business unit head for ophthalmics and head of strategic planning and business development for Novartis Pharma Services business in Russia. From 2002-2006 he was based in Zurich Switzerland as head of business planning for Pfizer AG. Igor Friedmann‟s professional expertise in the healthcare and pharmaceutical sectors dates back 10 years to 2001 when he was an Associate Consultant with the Boston Consulting Group‟s Zurich office. In that capacity, Mr. Friedmann supported leading global pharmaceutical companies in their business strategy development.
In his current role as Country General Manager Russia, CIS, Mr. Friedmann is responsible for overseeing the formulation and implementation of BD‟s strategic business development plan for the region. In this capacity, Mr. Friedmann manages high-level relations with the Company‟s strategic partners, both government and non-government, as well as with business partners and other key stakeholders. Mr. Friedmann is responsible for insuring that BD‟s global objectives to improve accessibility to healthcare solutions is efficiently and effectively adapted to the Russian environment. He is similarly mandated to develop, manage and motivate a diverse team of professionals with an emphasis on organizational and individual capacity building.
Mr. Friedmann is a member of the Board of Directors of the Association of Medical Device Manufacturers in Russia (IMEDA). In 2001, Igor Friedmann was awarded his Ph.D. in Life Sciences from the department of neurobiology of the Weizmann Institute of Science in Israel. In 1999, he received his Masters degree in Business Management from the Polytechnic University of New York (Israel branch) and in 1996; he was
awarded a Masters degree in Life Sciences (specializing in Molecular biology) from the Swiss Federal Institute of Technology in Zurich. Mr. Friedmann has written numerous publications on life science issues and speaks regularly as an industry expert at public forums and conferences.
Dr. Tatiana I. Grishina Clinical Immunology Chair Moscow State University Email:
Dr. Tatiana I. Grishina has over 30 years of broad clinical experience in general medicine. Her most recent work includes a study of immunology, viral infection and neurodegeneration induced and increased expression of TNF-alpha and Fas in the central nervous system. She has served as a professor of medicine at several esteemed universities. Dr. Grishina is responsible for managing the direction, planning, execution, and interpretation of clinical trials and research and the associated data collection activities. She also works to establish and approve scientific methods for design and implementation of clinical protocols, data collection systems, and final reports and to recruit clinical investigators, and negotiate study design and costs. Dr. Grishina‟s responsibilities also include directing Phase I through Phase 4 human clinical trials for company products under development. Responsibilities also include adverse event reporting and safety monitoring. She coordinates and develops reporting information for reports submitted to the FDA or other regulatory agencies, monitors adherence to protocols, and determine study completion.
Mark O. Henry, CPA
Chief Executive Officer Bach Pharma
2001-Current CEO, CFO, Bach Pharma, Inc., an International Development Company of Intellectual Property, Manufacturing, International Regulatory Agency Compliance, and an International Research Company for Pharmaceutical Products
1974 –2001 Treasurer CFI, Inc., Computerized Financial Information, CFI, Inc. is a computer service bureau offering consulting, business valuations and financial services to CPA firms, municipalities and general business clientele.
1987-1990 Stonebridge Developers: owned, developed and constructed residential condominium complex in Plaistow, NH, comprised of 64 townhouse units each 2,200 square feet.
1973-1988 Started the local accounting firm of Henry & Co., P.C., Sold Business.
1983-1988 Started Northeast Cheyenne Sales, Inc., Rochester, NY, Exclusive Aircraft Salesman Parts Distribution Center for Piper Aircraft Corporation, Vero Beach, Florida.
1982-1984 Elm Square Condominiums: designed and renovated a 35,000 square foot first class office building in Andover, MA.
1981-1983 Cash Energy Condo Associates: designed and developed a 60,000 square foot, first class office condominium building, North Andover, MA.
Arsen Kubataev, MD, MS, MBA Vice President, CIS Worldwide Clinical Trials Email:
As the Vice President for the CIS region of the Worldwide Clinical Trials (WCT, a global contract research organization) Dr. Arsen Kubataev is responsible for the company‟s regional operations and performance. He provides leadership and direction to over 300 employees in the CIS who support implementation of WCT clinical trial projects in Russia, Ukraine, Belarus, Georgia and Armenia, providing a full spectrum of services in clinical research and development.
Dr. Kubataev has extensive experience in the areas of corporate strategy, government relations, medical device and pharmaceutical sectors, international healthcare development, health services administration and international public health. His areas of expertise are leadership, strategic management, business development, advocacy and communications.
Prior to his work at WCT Dr. Kubataev served as the head of government relations for the Russian subsidiary of Medtronic, the world‟s leading medical technology company. Before Medtronic, he worked in various management capacities in international healthcare development with international non-for-profit and public health groups.
Dr. Kubataev holds an MBA from Duke University (Health Sector Management), an MS from New York University (Public Administration), and an MD from Saint-Petersburg Medical Academy (Epidemiology/Infectious Disease). He serves as a member of the Board of Directors for the AIDS Foundation East West, a Dutch not-for-profit agency working in Eastern Europe and Central Asia to reduce the impact of HIV/AIDS among vulnerable populations. Dr. Kubataev practiced medicine for two and one half years immediately after finishing medical school in 1989.
Ilona Kuraskua
Government Relations Manager Genzyme Russia Email:
Ilona Kuraskua has diversified work experience in industry and government in pharma and health care sector. She has been working at international pharmaceutical companies implementing market access strategy and health policy for innovative drugs and diagnostics products in Russia and CIS. Ilona graduated from Biology faculty of Moscow State Lomonosov University and received training in life sciences and biomedical research. She holds an MBA degree from the Stockholm School of Economics. Ilona currently works as Government Relations Manager at Genzyme Russia. Before joining Genzyme, she served as a representative of the U.S. National Institutes of Health, Office of AIDS Research in the US Embassy in Moscow, focusing on the development of US-Russia collaboration in health and science.
Anatoly Kutyshenko, MSc
Regulatory and Quality Assurance Manager
Amway Russia
Anatoly is a Technical Regulatory and Quality Assurance manager for Amway Russia. He is responsible for product compliance, regulatory policy and influence and quality assurance in the company nationwide operations. Anatoly received his second Master degree in Biochemistry from McGill University, Montreal, Canada.
Thore Larsgard Managing Director Russia and CIS
Eli Lilly Vostok S.A.
Thore Larsgard has served in Eli Lilly and Company for more than 16 years since he joined the company‟s Norwegian affiliate as Business Unit Manager in 1995. Mr Larsgard assumed the role of Managing Director of Lilly Russia and CIS in July 2007 with responsibility for developing Lilly business in this challenging and fast growing market. Mr Larsgard brings with him more than 23 years of corporate, business, marketing and sales experience in several markets apart from Russia. He was Lilly Managing Director in South-East Europe and Indonesia; he served as Global Marketing Manager at Lilly Headquarters in Indianapolis, USA, and Managing Director of Lilly affiliate in Norway. Prior to his career at Lilly he worked for Johnson & Johnson and Bayer Healthcare in marketing and sales positions. Mr Larsgard, a native of Norway, received his bachelor‟s degree in Business Administration from University of Oregon and Master of International Management degree from the Thunderbird School of Global Management in Arizona, USA.
Michel Manon Vice-President & General Manager Bristol Myers Squibb (Russia) Email:
Michel Manon has been General Manager of BMS Russia since 2007. Until that time, he held management positions in different countries and continents such as: Africa, Indochina, Israel.
As the General Manager of BMS Russia, Mr. Manon represents the company in different international and local associations. His mission in Russia is to establish the BMS Biopharma vision and strategies through partnership, in R&D in particular. Mr. Manon graduated from the University of Medicine - Intensive Care and Anesthesiology (Montpellier (France).
Maria Myagkikh, MD, PhD
Medical Director
Amgen LLC, Russia Email:
Dr. Maria Myagkikh is Head of R&D in Amgen LLC, Russia, holding a position of Medical Director, responsible both for Amgen clinical research in Russia and a wide range of medical, scientific and educational activities, leading a team of more than 20 employees. Her previous experience in the Pharma Industry (11 years) was in the field of clinical research. Before joining the industry, Maria was working as a researcher in one of the leading Russian and US scientific research centers, utilizing her solid background in clinical medicine and fundamental science. Her area of interest at that time was drug delivery, vaccine research, and human virology.
Garry Neil, MD
Corporate Vice President, Corporate Office of Science & Technology Johnson & Johnson Email:
Garry Neil, M.D. is Corporate Vice President, Corporate Office of Science and Technology (COSAT), Johnson & Johnson. In this role, Garry leads a team that catalyzes sustained growth for Johnson & Johnson by identifying and launching emerging technologies that underpin the creation of future businesses.
Garry has broad experience in science, medicine and pharmaceutical development. He has held a number of senior positions within J&J, most recently Group President, Johnson & Johnson Pharmaceutical Research and Development where he was responsible for maximizing existing strengths and leveraging collective resources to bring innovative new molecular entities (NMEs) to market quickly and cost effectively. Through a number of new initiatives he helped transform J&J‟s pharmaceutical R&D to a much more capable and productive organization and helped recruit a number of top scientists. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases, gained initial or new and/or expanded indication approvals.
Garry joined J&J in 2002 as Senior Vice President of Drug Development at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD). In 2005, Garry became President of J&JPRD, and in 2006, was promoted to Group President. Before joining J&JPRD, he held senior-level positions with Astra Merck Inc., Astra Pharmaceuticals, Astra Zeneca and Merck KGaA. He has also held a number of academic posts at a number of academic institutes including the Ludwig Institute for Cancer Research, the University of Toronto, the University of Iowa College of Medicine and the University of Pennsylvania (adjunct).
Garry has written more than 50 articles and book chapters. He holds a Bachelor of Science degree from the University of Saskatchewan and a medical degree from the University of Saskatchewan College of Medicine and completed his postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. He also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He is a Fellow of the American College of Physicians, a Fellow of the American College of Gastroenterology, a member of the American Association of Immunologists, and the Society for Clinical Trials, and a member of the Life Sciences Leadership Council of the University of Michigan. He is a member of the Boards of the Reagan Udall Foundation and the J&J Development Corporation and is J&J‟s representative to, and Chairman of, the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee, Chairman of the PhRMA Foundation Board, Chairman of the Scientific Advisory Board of the Center for Advanced Biotechnology and Medicine (Rutgers), a member of the Executive Committee of the Biomarkers Consortium, and Vice Chairman of the Board of Trustees of the Newark Boys Chorus School. He is also the 2007 discovery awardee of the American Geriatrics Society.
Alexey Petrenko
Corporate Affairs Director
Amway Russia
Alexey is responsible for corporate affairs in Russia which include media relations, government affairs and corporate social responsibility.
Vladimir Podgorodnichenko
Leading Researcher Medbiopharm Email:
Vladimir Podgorodnichenko, PhD (Biology) is a highly qualified specialist in biochemical, immunological and radioizotope research methods. His approaches are used in various research and medical institutes. Vladimir Podgorodnichenko took part in the development of blood substitutes with oxygen transport functions. New prospective radiopharmaceutics were developed with his immediate participation. Vladimir Podgorodnichenko is the author of 7 articles and roughly 15 patents. Now his main interest area is preclinical trials of new molecules.
Medbiopharm is a Russian Innovation Company, located in Obninsk, in the center of Russia. The main activity of the company is research and development of active molecules. We provide the full scope of work required for the conversion of active molecules into products demanded in a pharmaceutical or food market. Our key features are a strong project management team and the attraction of the leading Russian and foreign researchers as idea carriers and experts. Medbiopharm also has strong partner relationship with leading Russia research institutes.
Alexander Patalakha
SRA Manager
Coca-Cola Russia, Ukraine, Belarus Business Unit
Alexander Patalakha graduated 1984 Mendeleev Moscow Chemical Technological University, specializing in area physical-chemical research. 1984-1994 Scientist of Military Academy of Chemical Defense, areas of specializing physical-chemical analytical methods, toxicology, QSAR. 1988 has got PhD degree in chemistry. Published around 20 articles and reviews. 1994 - 2000 Coca-Cola Russia, Quality Assurance Manager, 2000 - 2003 Coca-Cola Central Asia, Technical Manager, 2003 - present, Coca-Cola Russia, Ukraine, Belarus business unit, SRA manager.
Brandon J. Price, PhD
Chief Executive Officer GalenBio, Inc. Email:
Dr. Brandon J. Price has more than 28 years experience in the biotechnology industry. Currently, he is Chief Executive Officer of GalenBio, Inc., an emerging vaccine platform technology company, developing a unique, totally synthetic “pathogen mimicking microparticle” technology for creation of human and veterinary vaccines.
He has been CEO of Cognate Therapeutics, a stem cell research company, President and CEO of Goodwin Biotechnology, Inc., a biologics contract manufacturing organization and CEO of CropTech Corporation, a transgenic plant protein company. Dr. Price has also held senior-level management positions at Cardinal Health, as Vice President of Biotechnology Services; BioReliance Corp., where he was a key member of the team that led the company public in 1997, and Ortho Diagnostic Systems, a Johnson & Johnson Company. He currently sits on the boards of Prairie Plant Systems, Inc., The Virginia Biotechnology Research Park, CONNECT Central Europe, and Research Triangle Europe. He also teaches bio-entrepreneurism courses at the University of Guadalajara (Mexico).
He holds a Ph.D. degree in Biophysics from the University of Michigan in Ann Arbor and is the author of more than 50 articles in the scientific and business literature.
R. Keith Randolph, PhD
Technology Strategist, Access Business Group LLC
Keith Randolph is Technology Strategist for Nutrilite and Artistry product development for Access Business Group LLC, and is located in Buena Park, Calif., USA.
Dr. Randolph joined Access Business Group in January 2000. His primary responsibilities include development of strategy for new technologies for the nutrition and beauty product lines sold through the direct selling business of Amway Corporation.
Sergey Reshetnikov Corporate Affair Manager, Diabetes Products Leader
Sergey joined Eli Lilly Vostok S.A. in March 2007 as Corporate Affairs Manager and Diabetes Products Leader acting as a focal point in developing and executing company‟s communications, advocacy and outreach programs. In January 2009, he assumed the role of Government Affairs Manager with responsibility for engaging and partnering with governmental authorities, policy and decision makers, top opinion leaders, patient advocacy groups, etc. to strengthen the overall image and position of the company as a leader in the Russian pharma market. Sergey has been instrumental in developing effective interactions with industry associations by actively participating in their activities/committees to monitor, analyze and influence changing healthcare environment.
Furthermore, he supports the company‟s major policy initiatives such as the Lilly - Foundation for the National Institutes of Health (FNIH) 5-year partnership project on the development of health related research in Russia.
Prior to joining Lilly, Sergey held senior GR and Communications positions at American pharmaceutical companies (Abbott Laboratories S.A., ICN Pharmaceuticals, Inc.) and at the Association of International Pharmaceutical Manufacturers (AIPM). Before joining the Big Pharma, he was a career diplomat with more than 10 years work experience at the Ministry of Foreign Affairs of Russia and the United Nations in New York. He holds a bachelor's degree in English and Spanish from Moscow State Linguistics University and a Professional Certificate from the United Nations Translation School in Moscow.
Yulia Reyser
Manager External and Regulatory Affairs Becton Dickinson Email:
Yulia Reyser is a Manager of External and Regulatory Affairs based in BD‟s office in Moscow, Russia where she is a member of the Russian affiliate‟s management team. Ms. Reyser is responsible for managing the Company‟s strategic policy issues, regulatory affairs and corporate positioning with key federal and regional level stakeholders in the Russian Federation.
Prior to joining BD, Ms. Reyser accumulated over 10 years of extensive experience in Russia‟s healthcare sector on behalf of leading global companies. Her work included management positions with public relations, regulatory and stakeholder relation‟s responsibilities at Boiron Laboratories, Eli Lilly and Company, Bayer CropScience and Pfizer International. Ms. Reyser‟s expertise in Russia‟s healthcare sector and her exceptional communication skills culminated in her role as Associate Director at the international PR firm Fleishman-Hillard Vanguard where she managed pan-European and global public relations initiatives on behalf of healthcare clients.
In her current role at BD, Ms. Reyser is responsible for working with key decision makers in Russia‟s executive and legislative bodies, as well as with international organizations and interested third parties to shape an effective and transparent policy and regulatory framework for medical devices and technologies. In addition,
Ms. Reyser closely coordinates with international and domestic partners for the implementation of BD‟s
corporate initiatives aimed at making healthcare solutions accessible and affordable to the population. She
engages with the media to raise awareness about healthcare issues and solutions, and works also with
healthcare professionals and opinion leaders for the development of public-private partnerships that lead to
training, education and other improvements in the sector.
Yulia Reyser earned her university degree in Journalism from the Moscow State Social University and has
completed numerous professional level strategic communication, management and leadership courses.
Rakhimdzan Roziev, PhD
Rakhimdzan Roziev, PhD medicine, is co-founder and Director of the innovative company
Medbiopharm, which has been researching, developing and producing original
pharmaceutical products for about 12 years. His professional experience includes the areas of
medicine, biopharmaceutics, and innovative venture projects. Three main focal points of his
interest are the creation of pharmaceutical project support system, effective project
management, and pharmaceutical industry development in Russia. Rakhimdzhan Roziev is
the author of more than 30 patents. He plays an active role in the social sphere of Obninsk
and Kaluga region.
Medbiopharm is a Russian Innovation Company, located in Obninsk, in the center of Russia. The main activity
of the company is research and development of active molecules. We provide the full scope of work required
for the conversion of active molecules into products demanded in a pharmaceutical or food market. Our key
features are a strong project management team and the attraction of the leading Russian and foreign
researchers as idea carriers and experts. Medbiopharm also has strong partner relationship with leading Russia
research institutes.
Igor Rukavishnikov
General Manager
Genzyme Russia
Igor Rukavishnikov has been working in the medical arena for the last 20 years,
encompassing cross-functional experiences in sales, marketing and business development
throughout Russia, CEE and Western Europe. He has experience in a variety of
therapeutic areas including Urology, Gastroenterology, Spine, and Speciality Care. Igor
currently holds the position of General Manager for Russia at Genzyme, one of the
world‟s foremost biotechnology companies. Previous to this role, he was working for
AstraZeneca Russia as Specialty Care Director. Igor graduated from the Russian State
Medical University.
Jay J. Schnitzer, MD, PhD
Associate Chief Medical Officer and Vice President
Boston Scientific Corporation
In April 2008, Dr. Schnitzer joined Boston Scientific Corporation as an Associate Chief Medical
Officer and Vice President, and was subsequently promoted to Chief Medical Officer and
Senior Vice President. His responsibilities at Boston Scientific Corporation include medical and
clinical oversight of the entire product lifecycle for all medical devices manufactured by three
business divisions of the company: endoscopy, urology/women‟s health, and neuromodulation.
This includes management and supervision of teams, and responsibility for an
annual budget of approximately $40 million. Research remains an important component of
his current position, with a focus on the design and execution of clinical trials for new
medical devices in the three business domains listed above.
Laszlo Stipkovits, DVM, PhD
Vice President of Preclinical Research
GalenBio, Inc.
Dr. Stipkovits has worked for over 40 years in the field of biotechnology. Currently, he is the Vice President of Preclinical Research of GalenBio, Inc., an emerging vaccine platform technology company, developing a unique, totally synthetic “pathogen mimicking microparticle” technology for creation of human and veterinary vaccines.
He has conducted research at several laboratories in Europe, such as Aarhus University, Denmark, INRA, Bordeaux, France, in University of Bern, Switzerland, Institut für bakterielle Tierseuchenforschung Jena, Germany) and in the USA, Stanford University, California, and University of Iowa, Iowa. He has extensive experience in the testing of the efficacy of several drugs and vaccines for treatment and prevention of mycoplasma infections and is a professor at the Veterinary Medical University, Budapest, Hungary.
He has broad experience both in research and in production sectors and he is an internationally recognized authority on mycoplasma-related health issues. He has developed several licensed veterinary vaccines and diagnostic products.
He holds a veterinary degree from the Veterinary Academy in Moscow and a Ph.D. from the Hungarian Academy of Sciences. He has published over 300 scientific articles related to mycoplasma infections and co-infections in humans and animals.
Steven L. Stroup, MD
Chairman of the Board Bach Pharma Email:
Bach Pharma, Inc. VP, Director of US Medical Research
Board of Directors
Sarah Cannon Cancer Center
Director of Radiation Oncology
(1984 -present) Steven L. Stroup, M.D., P.C. Self employed physician.
St. Thomas Hospital Director of Radiation Oncology
(1974 -1984)
Vanderbilt University
College of Medicine
Director of Radiation Oncology
(1974 -1981)
Andrey Strugovschikov Medical Director Abbot Laboratories, Moscow, Russia Email: PROFESSIONAL EXPERIENCE 08/2008 – present ABBOTT LABORATORIES, Moscow, Russia Medical Director 06/2005 – 08/2008 ASTRAZENECA, Moscow, Russia 06/2001 – 06/2005 BRISTOL-MYERS SQUIBB, Moscow, Russia Medical Director of PRI 09/1998 – 06/2001 YAMANOUCHI EUROPE, Moscow, Russia, Medical Director 1994 – 1998 MOSCOW REPRESENTATIVE OFFICE OF ASTRA AB, Moscow, Russia Medical Director 1990 – 1994 RUSSIAN PEOPLES' FRIENDSHIP UNIVERSITY, Moscow, Russia Member of Tutorial and Research Staff/Dept. of Internal Medicine
Susan Szathmary, MD, PhD
President and Chief Scientific Officer
GalenBio, Inc.
Dr. Susan Szathmary has more than 25 years experience in the biotechnology industry.
Currently, she is Chief Scientific Officer of GalenBio, Inc., an emerging vaccine platform
technology company, developing a unique, totally synthetic “pathogen mimicking microparticle”
technology for creation of human and veterinary vaccines.
She has been the founder of several biotechnology companies, Sterogene Bioseparations, Inc., a
chromatography company supplying major pharmaceutical companies for resins for
bioprocessing, Clarigen, Inc., a medical device company, and Carlsbad Research Org, Inc., a
testing company. She currently sits on the boards of CONNECT Central Europe, and Research Triangle Europe.
She holds an M.D. degree from Semmelweis University and a Ph.D. degree in Immunology from Szent Istvan
University. She has more than 40 published scientific and technical articles and holds over 10 patents in the life
sciences area.
Maria Tascheva
Government Relations Director, Russia
Abbott Global Government Affairs
Maria Tascheva has more than 16 years‟ experience in government affairs and public policy.
Prior to joining Abbott in 2011, she held position of General Director of Motorola Russia and
Chief Representative Officer of Motorola GmbH in Moscow (2007–2011); worked for OJSC
“VimpelCom” as Public Affairs Director, business development in Russian regions and CIS
countries (2002–2006). Maria has also served for about 8 years in a variety of positions at
the American Chamber of Commerce in Russia, supervising activities of 17 industry
committees and effectively promoting balanced AmCham members‟ interests with regard to
foreign direct investment, corporate governance, customs, IPR, taxation, standards &
certification. Previously (1991–1995) she worked for a Dutch company - Hunter Douglas Europe B.V. She
started her career at the USSR Ministry of Foreign Affairs.
Maria Tascheva holds a degree in English from the Moscow State Linguistics University by Maurice Thorez and
completed specialized upgrading courses on World Economy, Marketing and People‟s Management in the
American Institute of Business and Economics.
Larissa Tsibina
Medical Director
Bristol Myers Squibb (Russia)
Having graduated from the Medical Institute in Smolensk (Russia), Larissa Tsibina
successfully finished post-graduate Ccourses in Anesthesiology & Intensive Therapy and
received an MD and PhD in clinical pharmacology. She worked in clinical pharmacology for
7 years as an assistant professor. She has had wide-ranging experience in Clinical
Research and Medical Affairs since 1996.
She has been working for Bristol-Myers Squibb as Medical Director since August 2007.
Larissa Tsibina started her career in the pharmaceutical business in 2000, joining the
Medical Department at Eli Lilly. As Medical Director of BMS Russia, Dr. Tsibina has built an effective medical
affairs organization, which provides medical support across the company. Her mission is to develop medical and
scientific insight among medical communities in Russia.
Elisabeth Tsilikounas, PhD, MBA
Senior Director Emerging Markets Initiatives Genzyme Corporation Email:
Elisabeth Tsilikounas is currently Senior Director, Emerging Markets Initiatives at Genzyme. In this role, she partners with Genzyme‟s General Managers in emerging market countries to develop strategic relationships with governments and key institutions in support of short and long term commercial objectives. Elisabeth is currently working closely with the Genzyme Russia team on several strategic initiatives.
Previously, Elisabeth was Senior Director, New Business Initiatives, Latin America. In this role she was responsible for strategic partnership activities and new product development with a special focus on Brazil, Mexico, Chile and Argentina.
Recent accomplishments include the signing of agreements with renowned institutions such as the Oswaldo Cruz Foundation (Fiocruz) in Brazil in Chagas disease, the University of Chile in neurodegenerative diseases and the University of the Philippines in genetics.
Elisabeth started at Genzyme as Director, Corporate Development, responsible for all in-licensing activities for the Transplant Business Unit. She identified Mozobil®, initiated discussions with AnorMED and led the initial due diligence and negotiation of the first term sheet, which ultimately resulted in the acquisition of AnorMED for $580 million.
Prior to joining Genzyme, Elisabeth served as Director, Business Development at SangStat Medical Corporation until its acquisition by Genzyme in 2003. Her work experience also includes time spent at Hybrigenics as Manager, Business Development and at Sepracor, working in Scientific, Medical and European Affairs.
A former Research Fellow in the Gastroenterology Department, New England Medical Center, Boston, MA under a NIH Fellowship, Elisabeth holds a PhD in Biochemistry from Tufts University, Boston, MA, an MBA from Simmons Graduate School of Management, Boston, MA (Dean‟s Merit Scholar), and a Masters Degree in Biochemistry from the Université Pierre et Marie Curie, Paris, France (Magna cum Laude). She holds dual French-American citizenship.
Kirill Tverskoy
Moscow Medical Director Pfizer Email:
In 1991 Kirill Tverskoy graduated from the Department of Physical and Chemical Biology Moscow Institute of Physics and Technology with an MSc in Biophysics. After graduation he worked as the Research Associate at the Institute of Immunology, Russian Ministry of Health in Moscow. After completing his post-graduate thesis in Immunology and Allergology, Kirill earned a PhD in biology.
Kirill started his career in the pharmaceutical business in 1995 as the Clinical Research Associate at Omnicare Clinical Research CRO brunch in Moscow. In 2002 he joined Pfizer Russia as Clinical Trial Coordinator and then was promoted to Manager Clinical Research. Since 2007 he has held the position of Medical Director, Russian Representative Office of Pfizer H.C.P. Corporation (USA).
Anthony Wong General Manager Abbott Russia Email:
Manage with bottom-line responsibility the pharmaceutical operations consisting of 5 Business Units (HIV, Respiratory, Rheumatology, Anesthesia and) and 450 employees.
Achievements include: General Manager with 9 years experience in driving revenue and profit growth for 2 Fortune 500 company. Achieved organic growth from a level of USD 15 m to USD 130 m in turnover. Exceeded business goals by identifying market opportunities with strong sales potential. Demonstrated strategic marketing capabilities in building leading brands in 4 therapeutic areas. Meeting high standards in Business Ethics and Compliance through 3 successful audits.
Derek Yach Director of Global Health Policy PepsiCo
Derek Yach is Senior Vice President of Global Health and Agriculture Policy at PepsiCo where he leads the internal Global Human Sustainability Task Force and engagement with major international policy, research and scientific groups. Previously he has headed global health at the Rockefeller Foundation, been Professor of Public Health and head of the Division of Global Health at Yale University, and is a former Executive Director of the World Health Organization (WHO). Dr. Yach has spearheaded several major efforts to improve global health. At the WHO, he served as cabinet director under Director-General Gro Harlem Brundtland. Dr. Yach helped place tobacco control, nutrition and chronic diseases such as diabetes and heart disease prominently on the agenda of governments, non-governmental organizations and the private sector. He led development of WHO‟s first treaty, the Framework Convention on Tobacco Control, and the development of the Global Strategy on Diet and Physical Activity. Dr. Yach is a South African national. He established the Centre for Epidemiological Research at the South African Medical Research Council which focused on quantifying inequalities and the impact of urbanization on health. He has authored or co-authored over 200 articles covering the breadth of global health issues. Dr. Yach serves on several advisory boards including those of the Clinton Global Initiative, the World Economic Forum, IFPRI, GAIN, the Chicago Council and Vitality USA. Alexander Zhilov Executive Director The Center of Modern Medicine “Medicor”, Pharmaceutical Company Email:
2009-current The Center of Modern Medicine “Medicor”, Pharmaceutical Company, Executive Director
-Increased production of Medicor‟s many medical products, based on the platform of “Galavit” products
-Continued efforts to work with doctors and medical universities to develop new applications for the medical products through funding research as new scientific information continued to lead to expanded disease applications
-Greatly expanded the marketing and distribution of Medicor‟s medical products across the Russian federation and Eastern European countries
-Hired and trained a large sales force to expand and update the marketing strategies of the products to doctors and pharmacies
-Initiated negotiations with a United States company to distribute products in the United States and European countries
-Update manufacturing facilities to comply with government guidelines necessary to continue production in Russia and other countries
Irina P. Anokhina, MD, PhD
Deputy Director of Science,
Chief, Laboratory of Psychopharmacology
National Research Center on Addictions
Ministry of Health and Social Development
Moscow, Russia
Professor I.P. Anokhina received her M.D. degree from the 1st Moscow Medical Institute and then continued her education in the field of psychiatry. She earned her Ph.D. in 1962 and Dr.Sci in 1969. From 1966-1985, professor Anokhina served as Head of the Department of Psychopharmacology in the Institute of Forensic Psychiatry.
In 1985, when the Institute of Medico-biological problems of alcoholism was founded (later renamed to National Research Center on Addictions), professor Anokhina became its Deputy Director of Science, Head of the Department of medico-biological problems of addiction and Chief of the Laboratory of Psychopharmacology.
Professor Anokhina's professional interests are focused on multidisciplinary studies of the brain dysfunctions as the basis for many psychiatric disorders, including depression and drug abuse. Her current work is centered around an understanding of genetic vs. epigenetic mechanisms of drug addiction.
Professor Anokhina was elected a corresponding member of the Academy of Medical Sciences in 1984 and a member of the Academy of Medical Sciences in 1995. Currently she is a Chairman of the Scientific Council on the Problems of Addiction, Russian Academy of Medical Sciences.
Alexander I. Archakov, PhD
Director, Institute of Biomedical Sciences RAMS
Vice-President, Russian Academy of Medical Sciences
Alexander I. Archakov was born in Kashin, Russia in 1940. He graduated from the 2nd Moscow Medical Institute, took the post-graduate course and thereafter received a Ph. D degree in Biochemistry in 1976. From 1967-1989 he worked as a research teacher assistant, lecturer, the Head of the Biochemistry Laboratory and the Head of the Biochemistry Department. Since 1989, Professor Archakov has been the Director of the Research Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences. He is mainly interested in microsomal oxidation, development of cytochromes P450 database, computer-assisted analysis of protein structure and function, computer drug design, bioinformatics, proteomics, nanobiotechnology and nanomedicine. During the period of 1982-2007 he was awarded the A.N.Bakh Prize of the USSR Academy of Sciences, State Prize of the USSR, State Prize of the Russian Federation, State Prize of Russia, Order for the services to Homeland (IV Degree), Prize of the Government of Russia, Order for the services to Homeland (III Degree). A.I. Archakov is a member of the International Scientific Committees, council member of the International Human Proteome Organization (HUPO), member of the European Academy of Sciences; member of the European Society of Biochemical Pharmacology and Biochemical Society of Great Britain; member of the IUBMB and New York Academy of Science, chief Editor of the Journal "Biomedical chemistry", and chief editor of the “Nanoproteomics” section (the Journal “Proteomics”). In February 2011 Prof. Archakov was elected Vice-President of the Russian Academy of Medical Sciences.
Alexander Baranov, MD
Professor, Vice-President Russian Academy of Medical Sciences
Director, Scientific Centre of Children‟s Health of Russian Academy of Medical Sciences
Scientific interests: pediatrics, gastroenterology, public health
Scientific membership: Vice-President of European Pediatric Association, the Chairman of
the Executive committee of the Union of pediatricians of Russia, International Pediatric
Association, European Respiratory Society, the National Association of Clinical Nutrition.
Chief Editor of scientific journals: "Current Pediatrics", "Russian Journal of Pediatrics",
"Handbook of Pediatrician"
Member of Editoral Board of scientific journals: “Bulletin of RAMS”, "Questions of diagnostics in paediatrics",
"Doctor", "Clinical pharmacology and pharmacoeconomics", "General practitioner", "Medical Board", "Pediatric
Pharmacology", "G.N. Speransky‟s Pediatrics"
Member of Expert Boards and Committees: Chief out-of-staff specialist of the Ministry of Public Health and
Social Development - the chief pediatrician, chairman of the Scientific Council on Paediatrics of the Ministry of
Public Health and Social Development and the Russian Academy of Medical Sciences, member of the Ministry of
Education and Science of the federal state educational standards, member of the Scientific Council of the
Security Council Russia, member of the section “Medicine and Health Council” of the Russian Federation
Government Prize in Science and Technology, member of the Coordinating Council of the fundamental research
of state academies of science in 2008 – 2012.
Dr. Gail H. Cassell
Visiting Professor – Dept of Global Health and Social Medicine
Harvard Medical School
Dr. Gail H. Cassell is a Visiting Professor in the Department of Global Health and Social
Medicine, Harvard Medical School and Vice President of TB Drug Discovery of the not-forprofit
Infectious Disease Research Institute in Seattle. Dr. Cassell has recently retired as
Vice President, Scientific Affairs and Distinguished Research Scholar for Infectious
Diseases, Eli Lilly and Company in Indianapolis, Indiana. In this capacity among other
things, she was responsible for initiating and leading the not-for-profit Lilly TB Drug
Discovery Initiative launched in 2007. In 2003, she was one of two individuals at Lilly
who initiated and developed the Lilly Multidrug Resistant Tuberculosis (MDRTB)
Partnership. The partnership has resulted in company support to date of $135 million
dollars and is the largest philanthropic effort in Lilly‟s 135 year history. The partnership now involves over 20
partners, including WHO and CDC working in 80 countries. She is the former Vice President of Infectious
Diseases Drug Discovery and Clinical Development of Eli Lilly where she led the programs of a hepatitis C
protease inhibitor from the discovery phase to clinical candidate and the development of a new class of
antibiotics from clinical development to product decision . The Hepatitis C compound is now in phase III
clinical trials under the direction of Vertex. Prior to moving to Lilly in 1997, Dr. Cassell was the former Charles
H. McCauley Professor and Chairman of the Department of Microbiology at the University of Alabama Schools of
Medicine and Dentistry at Birmingham, a department which ranked first in research funding from the National
Institutes of Health during the decade of her leadership. She obtained her B.S. from the University of Alabama
in Tuscaloosa and in 1993 was selected by that institution as one of the top 31 female graduates of the 20th
century. She obtained her Ph.D. in Microbiology from the University of Alabama at Birmingham and was
selected as its 2003 Distinguished Alumnus.
She is a past President of the American Society for Microbiology (the oldest and single largest life sciences
organization with a membership of over 42,000). She was named to the original Board of Scientific Councilors
of the Center for Infectious Diseases, Centers for Disease Control and served as Chair of the Board. She has
served on the Advisory Board of the Director of National Institutes of Health, the Director of the Centers for
Disease Control, and the Secretary of Health and Human Services Advisory Council of Public Health
Preparedness, the FDA Science Board: Advisory to the Commissioner. Currently she is a member of the NIH
Science Management Board, the newly appointed “NIH board of Trustees” and the Advisory Council of the
Fogarty International Center of NIH. Since 1996 she has been a member of the U.S.-Japan Cooperative
Medical Sciences Program responsible for advising the respective governments on joint research agendas, (U.S.
State Department/Japan Ministry of Foreign Affairs). She has served on several editorial boards of scientific journals and has authored over 350 articles and book chapters. Dr. Cassell has received national and international awards and two honorary degrees for her research in infectious diseases, including the CDC Honor Award in Public Health for exceptional leadership and contributions in the development and implementation of CDC‟s Emerging Infectious Disease Plan 1997 and a Citation from the FDA Commissioner for her role as Chair of the review of science and technology at the FDA and the Report FDA: Science and Mission at Risk 2008 and the Emmy Klineberger-Nobel Award in 2008 by the International Organization for Mycoplasmology for outstanding and sustained research contributions to the field of mycoplasmology. She is a member of the Institute of Medicine (IOM) of the National Academy of Sciences and has recently completed a second 3-year term on the IOM Council, the governing board. She was elected in 2011 to membership in the U.S Council of Foreign Relations.
Dr. Cassell has been intimately involved in establishment of science policy and legislation related to biomedical research and public health. For nine years she was chairman of the Public and Scientific Affairs Board of the American Society for Microbiology; has served as an advisor on infectious diseases and indirect costs of research to the White House Office of Science and Technology Policy, and has been an invited participant in numerous Congressional hearings and briefings related to infectious diseases, anti-microbial resistance, and biomedical research. She has served two terms on the LCME, the accrediting body for U.S. medical schools as well as other national committees involved in establishing policies in training in the biomedical sciences. She is an Emeritus Member of the Board of Research!America and a former member and Chair of the Board of Directors of the Burroughs Wellcome Fund. She has recently completed terms on the Leadership Council of the School of Public Health of Harvard University, the Executive Committee of Columbia University Medical Center Board of Visitors, and the Johns Hopkins School of Nursing. Currently she is a member of the Morehouse School of Medicine Board of Trustees, and the Advisory Council of the University of North Carolina Gillings School of Global Public Health.
Valery Charushin Full member of the Russian Academy of Sciences Chairman of the Ural Branch of RAS, Director of I. Postovsky Institute of Organic Synthesis
Prof. Valery Charushin graduated from the Urals State Technical University (USTU, now the Ural Federal University) in 1973, and earned his PhD degree (Candidate of Chemical Sciences) in 1976 at the Department of Organic Chemistry of USTU under the guidance of Prof. Oleg N. Chupakhin.
Over the next 10 years Prof. Charushin did research in the field of heterocyclic chemistry at the Department of Organic Chemistry of the Urals State Technical University (Ekaterinburg, Russia). In 1981-1982 and in 1988 he worked in the Laboratory of Organic Chemistry in University of Wageningen (the Netherlands) under the guidance of Prof. Hеnk van der Plas, studying ring transformations of pyrimidines, 1,2,4-triazines and other azaaromatics by action of nucleophiles. In 1987 he received his doctoral degree (Doctor of Chemical Sciences), and became Full Professor of Organic Chemistry.
Current research interests of Prof. Charushin are associated with the development of new synthetic approaches to antivirals (for instance, the family of “triazavirin”) and antibacterials in the series of fluoroquinolones and other fluorinated heterocylces.
Prof. V. Charushin is author of over 500 publications in the fields of heterocyclic and medicinal chemistry, including the book «Nucleophilic Aromatic Substitution of Hydrogen”, New York: “Academic Press”, 1994 (authors: O.N. Chupakhin, V.N. Charushin and H.C. van der Plas), a number of chapters in “Advances in Heterocyclic Chemistry”, “Comprehensive Heterocyclic Chemistry” and “Progress in NMR Spectroscopy”, over 30 review articles and a great deal of papers in international journals. He is a member of the Editorial Boards for “Mendeleev Communications”, “Russian Chemical Reviews”, “Russian Chemical Bulletin”, “Russian Journal of Organic Chemistry” and other periodic issues.
Evgeny I. Chazov, MD, Professor
General Director, Russian Cardiology Research and Production Complex
Ministry of Health and Social Development of RF
Dr. Chazov was appointed Director of the USSR Cardiology Research Center in 1975.
Dr. Chazov graduated from the Kiev Medical Institute (Ukraine) in 1953. In 1954 he
received his Candidate of Medical Sciences from the 1st Moscow Medical Institute. Later in
1963, Dr. Chazov received his Doctorate from the Institute of Therapy.
From 1959-1975 he worked at A. L. Myasnikov Institute of Cardiology (previously known
as Institute of Therapy) as a researcher and later as a Deputy Director responsible for
scientific work of the Institute.
From 1987-1990, Dr.Chazov held the position of the Minister of Health of the USSR.
In 1990 he resumed his work as a Director General of the Cardiology Research Center (presently Russian
Cardiology Research and Production Complex). His scientific interests are diversified and cover a wide range of
problems: new methods of diagnosis and treatment of cardiovascular diseases, development of novel effective
drugs, etc. Dr. Chazov is a member of the Russian Academy of Sciences, member of the Russian Academy of
Medical Sciences.
He is also an Honorary President of the Russian Society of Cardiology. Dr. Chazov is an honorary member of
the American Heart Association and Fellow of the American College of Cardiology.
Valery N. Danilenko
Head of Laboratory
Vavilov Institute of General Genetics
Profеssor Danilenko has been the Head of the Laboratory of Genetics of
Microorganisms and head of Department of Post-Genomic Biotechnology at Vavilov
Institute of General Genetics, RAS, since 2006.
1971: graduated from Department of Genetics, Biological Faculty of Moscow State
University, 1977: PhD thesis in genetics, 1991: DSci. thesis in genetics, since 1994 -
Professor of genetics. In 1975 - 2006 V.N.Danilenko worked in research institutes
involved in the generation of strains and technologies for the microbiological and
pharmaceutical industry: State Research Institute of Genetics, All-Russian Research Institute of Antibiotics,
State Research Institute of protein synthesis. From 2002-2006, V.N. Danilenko headed State Research Institute
of Protein Synthesis.
Professor Danilenko‟s main scientific interests are the search for new targets and drugs for treatment of
bacterial infections and human diseases including cancer. Prof. Danilenko created and headed a new direction
of research in Russia: the study of the microbiota population in Russia. Prof. Danilenko is the Scientific
Secretary, Coordinating Council “Medical Equipment, Technology and Pharmaceutics” under Presidium of RAS.
Harvey V. Feinberg, MD
Institute of Medicine
Harvey V. Fineberg is President of the Institute of Medicine. He served as Provost of Harvard
University from 1997 to 2001, following thirteen years as Dean of the Harvard School of
Public Health. He has devoted most of his academic career to the fields of health policy and
medical decision making. His past research has focused on on the process of policy
development and implementation, assessment of medical technology, evaluation and use of
vaccines, and dissemination of medical innovations.
Dr. Fineberg helped found and served as president of the Society for Medical Decision Making
and has been a consultant to the World Health Organization. At the Institute of Medicine, he has chaired and
served on a number of panels dealing with health policy issues, ranging from AIDS to new medical technology. He also served as a member of the Public Health Council of Massachusetts (1976-1979), as chairman of the Health Care Technology Study Section of the National Center for Health Services Research (1982-1985), and as
president of the Association of Schools of Public Health (1995-1996).
Dr. Fineberg is co-author of the books Clinical Decision Analysis, Innovators in Physician Education, and The Epidemic that Never Was, an analysis of the controversial federal immunization program against swine flu in 1976. He has co-edited several books on such diverse topics as AIDS prevention, vaccine safety, and understanding risk in society. He has also authored numerous articles published in professional journals. Dr. Fineberg is the recipient of several honorary degrees and the Joseph W. Mountin Prize from the US Centers for Disease Control. He earned his bachelor's and doctoral degrees from Harvard University.
Robert Fontaine, MD, MSC
Senior Advisor, Field Epidemiology Training Program
Emerging and Re-Emerging Infectious Disease (Global Disease Detection)
Dr. Robert Fontaine has been the Expert Advisor to the Chinese Field Epidemiology Training Program (CFETP) of the Chinese Center for Disease Control and prevention since 2004. The CFETP is a 2-year field program designed to strengthen China‟s disease surveillance, applied epidemiology, and response capacities. Established in 2001, CFETP has trained more than 100 of China‟s top epidemiologists to develop and utilize surveillance, detect and respond to threats to the public health, and serve as the public health leaders of tomorrow. In 2007 the Government of China gave the Friendship Award to Dr. Fontaine for his work in developing the CFETP and in helping to resolve particularly problematic public health threats.
Prior to China, he served as a senior advisor to U.S. CDC‟s field epidemiology training programs in Jordan and Saudi Arabia. He has worked for the U.S. CDC since 1973 and investigated or guided investigations of over 200 outbreaks in the U.S., the Middle East, Central America, and China. These investigations have involved a broad range of topics including community and hospital-acquired infections, vector-borne and environmentally acquired infections, toxic exposures, and injuries. Robert has published 36 papers for public health journals and two book chapters throughout his career.
Dr. Fontaine received his Bachelor‟s degree in Entomology and Medical Doctorate from the University of California, Davis. He served in Epidemic Intelligence Service at the U.S. CDC from 1973 to 1975 and was a preventive medicine resident there. In addition, Robert earned a Master‟s of Science in Medical Parasitology from the London School of Tropical Medicine and Hygiene in London, England.
Georgii P. Georgiev
Scientific Director, Institute of Gene Biology
Russian Academy of Sciences
Professor Georgiev was the organizer and director of the Institute of Gene Biology of the Russian Academy of Sciences from 1990-2006. Since 2006, he has served as the scientific director.
Engelhardt Institute of Molecular Biology (1963-1990 - head of Department).
Severtsov Institute of Animal Morphology (1959-1963). Main achievements: discovery of nuclear DNA-like RNA (hnRNA), of hnRNP particles and determination of their structure, first visualization of nuclear skeleton (matrix), discovery and characterization of mobile elements in animal cells, discovery of protective antitumor protein Tag7 and its use for preparing antitumor vaccines. Member of Russian, European, German, Spanish and Norwegian Academies of Sciences, EMBO. Recipient of
state prizes of Russia and of USSR, Lenin prize.
Roger I. Glass, MD, PhD Director, Fogarty International Center Associate Director for International Research, NIH National Institutes of Health Email:
Dr. Glass was named Director of the Fogarty International Center and Associate Director for International Research by NIH Director Elias A. Zerhouni, M.D., on March 31, 2006. Dr. Glass graduated from Harvard College in 1967, received a Fulbright Fellowship to study at the University of Buenos Aires in 1967, and received his M.D. from Harvard Medical School and his M.P.H. from the Harvard School of Public Health in 1972. He joined the Centers for Disease Control and Prevention in 1977 as a medical officer assigned to the Environmental Hazards Branch. He was a Scientist at the International Center for Diarrheal
Disease Research in Bangladesh from 1979-1983 and returned to Sweden where he received his doctorate from the University of Goteborg. In 1984, he joined the National Institutes of Health Laboratory of Infectious Diseases, where he worked on the molecular biology of rotavirus. In 1986, Dr. Glass returned to the CDC to become Chief of the Viral Gastroenteritis Unit at the National Center for Infectious Diseases.
Dr. Glass's research interests are in the prevention of gastroenteritis from rotaviruses and noroviruses through the application of novel scientific research. He has maintained field studies in India, Bangladesh, Brazil, Mexico, Israel, Russia, Vietnam, China and elsewhere. His research has been targeted toward epidemiologic studies to anticipate the introduction of rotavirus vaccines. He is fluent and often lectures in five languages. Dr. Glass is a member of the Institute of Medicine of the National Academies of Science.
Igor Goryanin
Executive Director
Biomedicine Cluster, Skolkovo Email:
Igor Goryanin was born in 1962. He graduated from the Moscow Engineering Physics Institute, majoring in applied mathematics and received a Ph.D. in Physics and Mathematics, specialty biophysics. Since 1997 he has worked for one of the leading pharmaceutical companies, GlaxoSmithKline, in senior positions. Since 2005, Professor Grigoriev has been working at the University of Edinburgh (UK) in the field of bioinformatics and systems biology. He also heads the Laboratory of Biological Systems at the Okinawa Institute of Science and Technology (Japan).
Anatoly I. Grigoriev, Professor, DSc, PhD
Russian Academy of Sciences
Anatoly I. Grigoriev graduated from 2nd Pirogov Moscow Medical Institute in 1966. Since that time he worked in the Institute of Biomedical Problems (IMBP) in which he grew from a PhD student to Director (1988-2008). Currently Prof. Grigoriev is Scientific Leader of IMBP. Prof. Grigoriev‟s major interest of research is space biology and medicine, including mechanisms of human adaptation to space flight, methods of control and prognosis of piloted flights, gravitational physiology, ion and water balance and hormone regulation during space flights, as well as space telemedicine. Prof. Grigoriev made pivotal contributions to the basic theory and medical support of prolonged manned space flights as well as to major research programs in space life sciences.
He is a full member of the Russian Academy of Sciences (RAS) and Russian Academy of Medical Sciences, Coordinator of RAS Presidium Program „Basic Science for Medicine‟, member of the Council for Science, Technology and Education governed by the President of Russian Federation. Prof. Grigoriev‟s academic studies are combined with teaching at the Faculty of Fundamental Medicine, Moscow State University where he is Head of Chair of Aerospace and Extremal Medicine. In 2007 A.I.Grigoriev was elected Vice President of RAS to supervise academic studies in biology and biomedicine. He is Head of Coordinating Council „Medical Equipment, Technology and Pharmaceutics‟ established by Presidium of RAS in 2009.
Van S. Hubbard, MD, PhD
Director, NIH Division of Nutrition Research Coordination
Associate Director for Nutritional Sciences
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Dr. Hubbard is responsible for development of research initiatives and management of research programs related to the nutritional sciences and obesity.
Dr. Hubbard has been at NIH since 1976 in various positions and attained the rank of Rear Admiral and Assistant Surgeon General within the Commissioned Corps of the US Public Health Service prior to his conversion to civilian service in October 2010. He currently is chair of the NIH Nutrition Coordinating Committee and also is the Department of Health and Human Services liaison for the Interagency Committee on Human Nutrition Research. Dr. Hubbard serves as the NIH representative on numerous federal and non-federal committees and work groups including various Healthy People 2010 work groups. Dr. Hubbard is the co-lead for the Nutrition and Overweight Focus Area and the development of the Surgeon General‟s Initiative to address overweight and obesity. From 2005-2008, Dr. Hubbard served as the Senior Advisor to the Secretary of DHHS on Obesity in addition to his other positions. Additionally, he serves on several non-federal committees such as the Committee on Nutrition of the American Academy of Pediatrics and the International Advisory Board of the Medical Nutrition Education Project at the University of North Carolina at Chapel Hill. Other professional activities include serving as Professor of Pediatrics at the Uniformed Services University of the Health Sciences.
Dr. Hubbard has received many honors from the US government, such as the Certificates of Appreciation from FDA, DHHS, and USDA. He also has been awarded the USPHS Outstanding Service Medal, three Meritorious Service Medals, and the Surgeon General‟s Exemplary Service Medal, as well as two DHHS Secretary‟s Awards for Distinguished Service and three NIH Director‟s Awards. Dr. Hubbard is a Diplomate of the National Board of Medical Examiners and Fellow of the American Academy of Pediatrics. In 2000, he was made an Honorary Member of the American Dietetic Association. In 2002, he received the George Bray Founders Award from the North American Association for the Study of Obesity and in 2010 he received the Mickey Stunkard Lifetime Achievement Award from The Obesity Society. His major research interests are clinical nutrition, obesity, cystic fibrosis, and nutritional modulation of disease risk.
He received his Ph.D. in biochemistry and his M.D. from the Medical College of Virginia, Virginia Commonwealth University. Prior to coming to NIH, he completed an internship and his residency in the Department of Pediatrics at the University of Minnesota Hospitals.
Vadim T. Ivanov, DSci Director Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences Email:
V.T.Ivanov graduated from the Chemical Department of Moscow State University in 1960, defended his Ph.D. Dissertation in 1963 at the Institute for Chemistry of Natural Products (since 1992 Shemyakin&Ovchinnikov Institute of Bioorganic Chemistry) and completed his D.Sci. dissertation in 1974 at the same Institute. In 1988 V.T.Ivanov was named Director of the Institute.
V.T.Ivanov is a leading expert in chemistry and biology of peptides, author of over 400 publications in scientific Journals and of two peptide based pharmaceuticals. Prof. Ivanov‟s research interests at present are in systemic studies of the functional role of the entire population of peptides (the peptidome) in various biological systems as well as in application of peptidomic research to development of new pharmaceuticals and new diagnostics.
Eugenia A. Koshkina
MD, PhD (doctoral), professor
Director of the National Research Center on Addictions, Russian Federation Ministry of Health and Social Development
Eugenia Koshkina graduated from the Pediatric Faculty of the 2nd Moscow Medical University in 1968. After graduating worked in the department of Social Hygiene and Healthcare Provision of the Moscow Research Institute of Epidemiology and Microbiology as a junior researcher, then as a senior researcher. In 1975 defended a PhD dissertation (candidate‟s) with the theme: “Integral assessment of health condition among children of pre-school and school age”. From 1976 to 1986 headed the sub-division of Requests and Information of the Republic Department of Research and Medical Information at the same department of Social Hygiene and Healthcare Provision. From 1978 to 1986 Eugenia Koshkina headed the sector of Medical-Labor Expertise at the Central Institution of Labor Expertise and Employment for Handicapped.
In 1986 Eugenia Koshkina started working at the National Research Center on Addictions as the head of the Epidemiology department. The PhD (doctoral) dissertation with the theme “Developing models of drug use situation prognoses assessment and strategy of prevention activities”. In 1999 Eugenia Koshkina was awarded the title of professor. During 2005-2009 acted as the chief expert in addictions among youngsters at the Ministry of Health. For several years acts as the Permanent Correspondent of the Pompidou Group of the Council of Europe.
Eugenia Koshkina is the coordinator for a large number of projects that were implemented by the Department both within Russia and in cooperation with international partners. Only between 1998 and 2010 she was the scientific supervisor for more than 15 candidate‟s PhD dissertations, and for 3 doctoral ones.
Starting with 21 April 2010 Eugenia Koshkina was appointed as the director of the National Research Center on Addictions.
Marya Levintova, PhD
International Program Officer for Russia, Eurasia and Arctic Affairs
Fogarty International Center
National Institutes of Health
Dr. Levintova joined the Division of International Relations, Fogarty International Center, National Institutes of Health (NIH), in May 2006 with responsibilities covering Russia, Eurasia and the Arctic regions. Prior to joining NIH in 2006, Dr. Levintova was a postdoctoral research fellow at the Alcohol Research Group, School of Public Health, University of Berkeley, where she analyzed the impact of alcohol control policies on alcohol consumption and mortality in the Russian Federation. For about 5 years, Dr. Levintova has been examining health-related policies, legislation, and programs in the countries of the former Soviet Union, in particular focusing on non-communicable diseases. Dr. Levintova is a recipient of the Fulbright Scholar award for the study of the impact of the demographic changes on health-related legislation and policies in the Russian Federation.
Dr. Levintova immigrated to the United States from the Soviet Union in 1989. She holds a Ph.D. in Clinical Psychology from Alliant University/California School of Professional Psychology, and a B.A. from the University of Redlands. Her research interests include development and implementation of public health policies and legislation; tobacco, alcohol, and drug abuse control, and the interplay of multi-sectoral stakeholders in the policy decision-making process. Dr. Levintova is fluent in Russian.
Sergey V. Netesov, PhD, DSci
Vice Rector
Novosibirsk State University
Professor Netesov has been a Vice-Rector for Research at the Novosibirsk State University since November, 2007. Prior to this appointment, he worked at the State Research Center of Virology and Biotechnology “Vector” for 30 years and held a position of Deputy Director for Research starting in 1990. He graduated from Novosibirsk State University (1975); joined Vector (1977); received Ph.D. (1983) and Doctor of Biology degree (1993). He is the Corresponding member of Russian Academy of Sciences (1997), Member of European Academy of Sciences, American Society for Virology, American and European Biosafety Associations, etc. He received two Russian Government Awards (1998 and 2006). His research interests include virology and biotechnology. He is the author of 120 more publications in Russian and international journals.
Ludmila M. Ogorodova, MD Vice-rector for academic affairs and post-graduate studies at the SEI of HPE SSMU of the Ministry of Health and Social Development of Russia
Professor, RAMS academician, Honored scientist of the Russian Federation Email:
Ludmila M. Ogorodova was named vice-rector for academic-affairs and post-graduate studies in 1998. Since 1998 she has served as the Chief of the Department of Faculty Pediatrics, teaching a course on childhood diseases.
Dr. Ogorodova graduated from Tomsk Medical University in 1980, and received her M.D. in 1995 and her title of a professor in 1997. Professor L. Ogorodova has received a title of honor “Honored Scientist of the Russian Federation”, and, is a RAMS academician (since 2007).
Dr. Ogorodova's research interests are dedicated to urgent problems of pediatrics: studying the molecular and genetic bases of clinical polymorphism of allergic and broncho-pulmonary diseases in children, improving methods of their diagnostics and treatment.
Ludmila Ogorodova is a famous scientist in the sphere of pediatric pulmonology, allergology and immunology. She performed fundamental studies concerning molecular mechanisms of allergic inflammation in atopic diseases (atopic dermatitis, bronchial asthma), the role of cytokines, their receptors and other signal systems in the regulation of inflammation. One of the directions of her scientific research has been targeted towards studying various clinical variants of bronchial asthma in children and adults from the points of view of the evidence-based medicine, immunological, morphological features of severe, uncontrolled form of the disease, molecular mechanisms of therapeutic (including steroid) resistance. The scientific group of Ludmila M. Ogorodova is a member of two consortia of the EU: EuroPrevall and GABRIEL.
Susan B. Shurin, MD
Acting Director
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Susan Shurin, MD, is the Acting Director, National Heart, Lung, and Blood Institute (NHLBI). She joined NHLBI in 2006 as the Deputy Director, and has been Acting Director since December 2009. She is responsible for the scientific and administrative management of the intramural and extramural activities of the NHLBI, and oversight of the Institute‟s clinical research portfolio. Dr. Shurin represents the NHLBI in activities across the National Institutes of Health and the Department of Health and Human Services. The NHLBI, third largest of the 27 Institutes and Centers at NIH, has an annual budget of over $3.1 billion, and manages a complex portfolio of basic, clinical, translational and epidemiologic research. Institute-conducted research takes place on the campus in Bethesda MD and in Framingham MA. The bulk of the Institute‟s resources are allocated to support extramural research across the US and across the globe. Dr. Shurin is engaged in multiple trans-NIH research and administrative activities, and in global health research on non-communicable diseases.
Before joining the NHLBI, Dr. Shurin was professor of Pediatrics and Oncology at Case Western Reserve University; director of Pediatric Hematology-Oncology at Rainbow Babies and Children‟s Hospital; director of Pediatric Oncology at the Case Comprehensive Cancer Center; and vice president and secretary of the Corporation at Case Western Reserve University in Cleveland, Ohio. Dr. Shurin received her education and medical training at Harvard University and the Johns Hopkins University School of Medicine. Her laboratory research focused on the physiology of phagocyte function, recognition and killing of pathogens; mechanisms of hemolysis; and iron overload. She has been active in clinical research in many aspects of pediatric hematology-oncology, including participation in the Children‟s Cancer Group, Children‟s Oncology Group, multiple studies in sickle cell disease and hemostasis. She has
had leadership roles in multiple professional organizations.
Vladimir I. Starodubov, Prof., MD, DSc
Russian Academy of Medical Sciences
The development, validation and study of the legal, organizational, methodological and economic aspects of the country's health care system reform, the study of medical-demographic processes and health indicators, the development of scientific monitoring of the health system in the contemporary social and economic conditions, building the model of health accounts and efficient use of audit of public resources industry are among Prof. Starodubov‟s main research interests.
The theory, methodology and implementation of medical insurance system in the Russian Federation had been developed with the active participation of Prof. Starodubov. He directed the development and adoption of the concept of governance and financing reform of public health in the Russian Federation.
From 1998-1999 Prof.Starodubov was the Minister of Health of the Russian Federation. From 2004-2008, he was Deputy Minister of Health and Social Development. Currently he is the official representative of the Russian Federation at the Executive Committee of the World Health Organization.
Gennady T. Sukhikh, MD
Professor, Academician of Russian Academy of Medical Sciences
Honored Master of Science of the Russian Federation
Dr. Sukhikh is the Director of the Federal State Institution “Research Center for Obstetrics, Gynecology and Perinatology” of the Ministry of Healthcare and Social Development of the Russian Federation, Head of the Department of Obstetrics, Gynecology, Perinatology and Reproductology of the Faculty of Postgraduate Professional Education of Physicians of the 1st Moscow State Medical University named after I.M. Sechenov. For over 20 years he has been the Head of the Laboratory of Clinival Immunology of the Center. Under his purview, two new laboratories were organized: laboratory of the molecular-genetic methods, and laboratory of genomics and epigenetics.
Scientific interests: a wide range of the priority trends of the modern reproductive medicine and molecular biology. Fundamental research in the field of immunology of reproduction, molecular genetics at various pathologic conditions in gynecology, obstetrics, and perinatology; study of possibilities of usage of various types of autologious and allogenic stem and progenitor cells for treatment of various diseases. Dr. Sukhikh is the author of more than 560 scientific papers (including 18 articles in foreign journals for the last 9 years) and 12 monographs, 15 inventor‟s certificates.
Dr. Sukhikh is the principal investigator in a number of state contracts held within the framework of Federal Target Programs: “Development of the method of diagnosis and prognosis of hyper-proliferative diseases of organs of female reproductive system based on new molecular-genetic markers” (2011-2013); “Investigation of immune and regulatory features of primary cultures of stem cells of mesenchymal and ectodermal origin” (2009-2013); “Elaboration of means of restoration of male reproductive function with autologious and allogenic stem and progenitor cells cultures” (2007-2010); “Development of new and improvement of existing technologies for diagnosis and treatment of reproductive function disorders in children and adolescents” (2007-
2010); “Development of methods for improvement of technologies of diagnosis and treatment of diseases in newborns” (2007-2010); “Development of new technologies for management of pregnant women with a high risk of complications” (2007-2010).
Vsevolod A. Tkachuk, Academician, Professor, PhD, DrSc, Biochemistry
Dean, Faculty of Fundamental Medicine
M.V. Lomonosov Moscow State University
Vsevolod Tkachuk graduated with honors from the Biological Faculty MSU in 1970. He received his Ph.D. from Biological Faculty MSU (1973) and his Dr.Sc. from the Cardiology Research Centre in 1986. He became Professor of Biochemistry in 1988. He became an academician of the Russian Academy of Sciences (2006) and an academician
of the Russian Academy of Medical Sciences (2000).
He worked as a Junior Research Scientist and then Senior Research Scientist in the Department of Biochemistry, Biological Faculty MSU since 1973. Since 1982, Vsevolod Tkachuk has been the Head of the Laboratory of Molecular Endocrinology at the Institute of Experimental Cardiology, Cardiology Research Centre. He is a Chief of the Department of Biochemistry at the Institute of Experimental Cardiology, Cardiology Research Centre since 1987. He is also a the Chairman of the Department of Biological and Medical Chemistry (currently named as Biochemistry and Molecular Medicine) of the Faculty of Basic Medicine MSU. Since 2000, he has been a Dean of the Faculty of Fundamental Medicine MSU.
Prof. Tkachuk is a biochemist and cell biologist. His field of expertise includes receptor activation and signal transduction, gene and cell therapy, regulation of blood vessel growth and remodeling. He has developed educational program in molecular medicine for medical students, which incorporates all current knowledge in the field of innovative therapeutic approaches development for patients with severe diseases. He is an active researcher and lector, giving lectures not only to biology students and faculty of Fundamental Medicine, but he also gives public lectures, focused on the progress of modern biomedical science.
Prof. Tkachuk was a coordinator of government US-Russia collaboration in the field of biomedical research; he also coordinates a government collaboration program between Australia and the Russian Federation. Prof. Tkachuk is a member of the International Society of Angiology, International Society of Heart Research, International Society of Vascular Biology, International Society of Atherosclerosis and the International Society of Pathophysiology.
Edward L. Trimble, MD, MPH
Head, Gynecologic Cancer Therapeutics and Quality of Cancer Care Therapeutics
Clinical Investigation Branch, Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute, National Institutes of Health
Following graduation from Harvard College and the Johns Hopkins University School of Medicine, Edward L. Trimble trained in obstetrics and gynecology at the Vanderbilt University Medical Center. He earned a master‟s degree in public health from the Johns Hopkins School of Hygiene and Public Health, then completed a fellowship in gynecologic oncology at Memorial Sloan-Kettering Cancer Center. He is board-certified in obstetrics and gynecology, as well as in gynecologic oncology, by the American Board of Obstetrics and Gynecology.
In 1991, he joined the National Cancer Institute, where he is now Head, Gynecologic Cancer Therapeutics and Quality of Cancer Care Therapeutics, Clinical Investigation Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis. His duties involve scientific liaison with the Gynecologic Oncology Group and the American College of Surgeons Oncology Group, as well as oversight of issues involving the elderly, minorities, women‟s health, international collaboration, cost, cancer health disparities, health-related quality of life and patient-reported outcomes in NCI-sponsored treatment trials. He practices gynecologic oncology at the NIH Clinical Center and Johns Hopkins Hospital, where he is an Associate Professor of Gynecology & Obstetrics and Oncology.
Dr. Trimble has co-authored 59 peer-reviewed articles and 18 book chapters. For his work at NCI he has
received two Public Health Service Commendation Medals, 6 NIH Merit Awards, and the NCI Director‟s Gold
Star Award.
Victor Tutelyan, MD, PhD
Director of Institute of Nutrition
The Russian Academy of Sciences
Dr. Tutelyan was named Director of the Institute of Nutrition of the Russian Academy of
Medical Sciences on December 12, 2000.
Dr. Tutelyan graduated from I.M. Sechenov‟s Ist Moscow Medical Institute (at present I.M.
Sechenov‟s 1st Moscow State Medical University), and received his PhD (Biochemistry) from
the Institute of Nutrition of the Russian Academy of Medical Sciences (RAMS) in 1968. He
joined the Institute of Nutrition in 1965 as a post-graduate student. Then he worked as a
Senior Scientist at the Laboratory of Nutrition Enzymology. Dr. Tutelyan became the Head of
Nutrition Enzymology Lab in 1976. He was a Deputy Director of the Institute of Nutrition
from 1980-2000 and took the position of the Director in 2000. Since 1994 Dr. Tutelyan has been the Head of
Food Hygiene and Toxicology Department at the I.M. Sechenov‟s 1st Moscow State Medical University.
Dr. Tutelyan is a Full Member (Academician) of the Russian Academy of Medical Sciences and Chief Scientific
Secretary of the RAMS Presidium. He is a leading Russian nutritionist, WHO Expert on Nutrition and Food
Safety, and an ILSI-Europe Board of Directors Member. Dr. Tytelyan is the Chairman of the Scientific
Committee on the Medical Problems of Nutrition. The basic fields of Dr. Tutelyan‟s research interest are Food
Safety, Toxicological Biochemistry and Nutriology.
Michael Ugrumov, MD, PhD
Head of Laboratory, Institute of Developmental Biology, RAS
Head of Laboratory, Institute of Normal Physiology, RAMS
Prof. Ugrumov graduated from Moscow University Medical School in 1970 and received
PhD from the Institute of Evolutionary Physiology and Biochemistry USSR Academy of
Sciences in 1974. He was a Senior Researcher at the Institute of Human Morphology
RAMS (1974-77) and the Institute of Developmental Biology RAS (1977-87). M. Ugrumov
is the Head of the Laboratory at the Institute of Developmental Biology from 1987 and at
the Institute of Normal Physiology since 1996. He got a Professorship in Pharmacology
and Radiobiology in 1996 at the State Medical University, Moscow, Russia and was elected
as a Corresponding Member of the Russian Academy of Sciences in 1997 and as a full
Academician of the Russian Academy of Sciences in 2006. M. Ugrumov is a Counsellor of
the President of the Russian Academy of Sciences (RAS) on International Scientific Cooperation, a member of
the Scientific-technical Council at Chairman of the Federal Assembly of RF, and Vice-president of Russian
Physiological Society. He was a Visiting Prof. at : Univ. Medical School, Tokushima (Japan) in 1988-89; Medical
University of Ulm (Germany) in 1993; University of Tours (France) in 1998, 2000; University P. et M. Curie
(Paris, France) in 1993-2010. Honours: Orbeli Prize of the Russian Academy of Sciences in Physiology, 1995,
Professorship and Prize of the Burroughs Welcome Fund and the Federation of American Societies for
Experimental Biology, 2001.
Field of expertise: Neurosciences (Development, Neuroendocrinology, Neurodegenerative Diseases),
Management in Science. Main studies of M. Ugrumov are devoted to: (i) the development of the
neuroendocrine regulations in ontogenesis with focus on the development of the hypothalamus, differentiation
of peptidergic and monoaminergic neurosecretory neurons and the establishment of the pathways for
neurohormone transfer to the cerebral ventricles and hypophysial portal circulation; (ii) the regulation of the
neuron genesis and differentiation by extracellular signals playing a role of morphogenetic factors; (iii) the
mechanisms of the brain plasticity and their regulation by signalling molecules in norm and under
neurodegenerative diseases.
Valentin V. Vlassov, Ph.D., DSci
Director, Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch
The Russian Academy of Sciences
Vice President of the Siberian Branch of the Russian
Academy of Sciences
Dr. Vlassov graduated from Novosibirsk State University in 1969 and joined the Laboratory of Natural Biopolymers at the Institute of Organic Chemistry (SBRAS). The Laboratory was transformed in 1996 to the Institute of Chemical Biology and Fundamental Medicine (SBRAS). In 1996 Dr. Vlassov became director of this Institute. He is a full member of Russian Academy of Sciences, and since 2008 he has been vice president of the Siberian Branch of RAS and Chairman of the United Biological Council of SB RAS.
Dr. Vlassov‟s main research interests are the investigation of circulating nucleic acids, the development of methods for early cancer diagnostics and the design of anticancer nucleic acid –based therapeutics.
Mary Elizabeth Wilson, MD
Associate Professor of Global Health
Harvard School of Public Health
Mary E. Wilson is Associate Professor of Global Health and Population at the Harvard School of Public Health. Her academic interests include the ecology of infections and emergence of microbial threats, travel medicine, tuberculosis, and vaccines. Her undergraduate degree in French, English, and philosophy was awarded by Indiana University; she received her M.D. from the University of Wisconsin and completed an internal medicine residency and infectious disease fellowship at the Beth Israel Hospital in Boston (now Beth Israel-Deaconess Medical Center). She was Chief of Infectious Diseases at Mount Auburn Hospital, a Harvard-affiliated community teaching hospital in Cambridge, Massachusetts for more than 20 years. She is a Fellow in the Infectious Diseases Society of America and the American College of Physicians. She has served on the Advisory Committee for Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC), the Academic Advisory Committee for the National Institute of Public Health in Mexico, and on four committees for the Institute of Medicine of the National Academies, including the Committee on Emerging Microbial Threats to Health in the 21st Century, whose report (Microbial Threats to Health: Emergence, Detection, and Response) was released in March 2003. She has worked in Haiti at the Albert Schweitzer Hospital and leads the Harvard-Brazil Collaborative Course on Infectious Diseases, which is taught in Brazil. In 1996 she was a resident scholar at the Bellagio Study Center, Italy and in 2002 she was a Fellow at the Center for Advanced Study in the Behavioral Sciences in Stanford, California. She was member of the Pew National Commission on Industrial Farm Animal Production whose report, Putting Meat on the Table: Industrial Farm Animal Production in America, was released in the spring of 2008. A former GeoSentinel Site Director (Cambridge), she now serves as a Special Advisor to the GeoSentinel Surveillance Network, a global network. She has lectured and published widely, serves on several editorial boards, and is an associate editor for Journal Watch Infectious Diseases. She is the author of A World Guide to Infections: Diseases, Distribution, Diagnosis (Oxford University Press, New York, 1991), senior editor, with Richard Levins and Andrew Spielman, of Disease in Evolution: Global Changes and Emergence of Infectious Diseases (New York Academy of Sciences, 1994), and editor of the volume New and Emerging Infectious Diseases (Medical Clinics of North America) published in 2008. She joined the Board of Trustees for ICDDR,B (International Centre for Diarrheal Disease Research, Bangladesh) in 2009 and is a member of the Board of Scientific Counselors for the CDC, the FXB-USA Board, and the APUA Board of Directors.
Vitaly V. Zverev
I.I.Mechnicov Research Institute of Vaccines and Sera
VITALY V. ZVEREV was born on June 3, 1952. In 1975, he graduated from the therapeutic faculty of the Volgograd State Medical Institute. In 1985 and 1995 accordingly, he defended theses for the academic states of candidate (PhD) and doctor (DSc) of sciences. On December 12, 1999, he was elected a Corresponding Member and on June 4, 2002 – a Full Member of the Russian Academy of Medical Sciences (RAMS).
Accomplishments: Full Member of RAMS, Doctor of Biological Sciences, Professor, Director of the RAMS establishment I.I.Mechnicov Research Institute of Vaccines and Sera, Academician Secretary of the RAMS Department of Preventive Medicine, the Chief of the department of microbiology, virology and immunology in the I.I. Sechenov First Moscow State Medical University (MSVU) of the Ministry of Health and Social Development of the Russian Federation, two-time winner of the Russian Federation Government Prize in the field of science and engineering (1998 and 2006). He is the author of more than 250 scientific publications including 8 monographs and 3 textbooks.
V.V. Zverev‟s fundamental research investigates the mechanisms of virus-cell interactions, molecular biological structure and regulation of expression of virus genes, structure and function of viral proteins to development and the introduction of vaccinal and immunobiological preparations.
V.V. Zverev is the Vice-President of All-Russia Scientific Practical Society of Epidemiologists, Microbiologists and Parasitologists, the Head of the Problem Commission on “Measles, Mumps, Rubella,” the Chairman of the Scientific Council on “Vaccinology,” and the Editor–in-chief of the journal “Microbiology, Epidemiology and Immunobiology” and the informational bulletin “Vaccination.”